April 22 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a late-stage trial studying it as an add-on treatment for schizophrenia, sending its shares down nearly 7% in after-market trade.
So Cobenfy doesn’t make a difference if used with another antipsychotic.
I’m glad I didn’t switch to Cobenfy.
I’m on Cobenfy and Haldol. Clozapine was better than Cobenfy in my view.
Within the positive testimonies, there are some that are extremely positive, where the testimonies talk about socializing better, improvements in negative symptoms, losing all the weight they previously gained with the conventional antipsychotics they were taking before. And they have their positive symptoms under control.
The problem is that schizophrenia is very heterogeneous, and so is the response to antipsychotics.
Are you referring to positive or negative symptoms? If you’re taking Cobenfy along with Haldol and you’re experiencing some negative symptoms, these could be caused by the Haldol.
So it’s a weak antipsychotic like ability, got it will try to import it